Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib in Transfusion-Dependent Myelofibrosis
NCT02515630Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of momelotinib dihydrochloride in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by GSK. Started Jan 2016; status: completed.
02
Drugs
momelotinib dihydrochloride
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT02515630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02515630.